Black Diamond Therapeutics (BDTX) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunic (IMUX) has outperformed Black Diamond Therapeutics (BDTX) over the past year, losing 15.8% versus a loss of 53.2%. Over five years, BDTX leads with a -77.6% price change compared with -91.3% for IMUX. Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $103.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | IMUX |
|---|---|---|
| Share price | $1.81 | $7.56 |
| Market cap | $103.72M | $103.15M |
| 1-day change | -1.09% | -0.92% |
| YTD return | -24.69% | +41.57% |
| 1-year return | -53.20% | -15.81% |
| 5-year return | -77.63% | -91.28% |
| EPS (TTM) | $-0.75 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $17.43 |
| 52-week low | $1.60 | $5.06 |
| Distance from 52-week high | -63.36% | -56.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +452.49% | +469.97% |
| Average volume | 624.32K | 284.68K |
| Shares outstanding | 57.30M | 13.64M |
| Employees | 21 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed BDTX by 37.4 percentage points over the past year.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Healthcare · Biotechnology · 21 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Healthcare · Biotechnology · 100 employees
BDTX vs IMUX FAQ
Which is bigger, Black Diamond Therapeutics or Immunic?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $103.15M for Immunic (IMUX).
Which stock has performed better over the past year, BDTX or IMUX?
IMUX returned -15.81% over the past 12 months, compared with -53.20% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Immunic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.